Celebrating the 20th Anniversary of the GORE® EXCLUDER® Device
With two decades of evolution and more than 300,000 patients treated* worldwide, this trusted, market-leading EVAR device continues to advance patient care
With two decades of evolution and more than 300,000 patients treated* worldwide, this trusted, market-leading EVAR device continues to advance patient care
Device is proven to reduce the risk of reintervention for patients with pancreatic and other cancers that obstruct the bile duct; replacement program can help limit overall costs of palliative care
Gore has appeared in every edition of the rankings, published annually in Fortune magazine. The company is among just 12 “Great Place to Work Legends” to hold this distinction.
Real-world outcomes of TEVAR procedures performed with new delivery system that enables positioning and angulation control during stent graft deployment
New three-layer hybrid biomaterial, ideal for TAR procedures, offering permanent strength and rapid tissue generation for single-stage repairs
Completion of follow -up paves way for REDUCE Clinical Study data submission to FDA for PFO indication
The pioneering Dr. Jemison, who flew aboard the Space Shuttle Endeavour, will address vascular surgeons at the 2014 SCVS symposium in Carlsbad, Calif.
Proven, durable device leads the market, continues to impact lives
W. L. Gore & Associates named as a winner of the eighth annual Pinnacle Award
Conformable GORE® TAG® Thoracic Endoprosthesis First to Receive Indication for Aneurysm, Trauma and Dissection